A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2018
Price : $35 *
At a glance
- Drugs BCD-132 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biocad
- 16 Jul 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.
- 16 Jul 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2019.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.